These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37641582)

  • 41. Anticoagulation, bleeding, and clotting at donor plasmapheresis.
    Evers J; Taborski U
    J Clin Apher; 2018 Aug; 33(4):538-540. PubMed ID: 29575131
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of donor's characteristics on plasmapheresis products: insights for a personalised approach.
    Merolle L; Marraccini C; Vurro F; Parisi M; Di Bartolomeo E; Bonvicini L; Broccoli S; Rossi PG; Baricchi R; Pertinhez TA
    Blood Transfus; 2020 May; 18(3):170-175. PubMed ID: 32281927
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A prospective trial assessing the safety and efficacy of collecting up to 840 mL of plasma in conjunction with saline infusion during plasmapheresis.
    Buzza M; Marks DC; Capper H; Cassin E; Badcock CA; Reid S; Kwok M; Yang H; Lee J; Corrigan C; Hartkopf-Theis T; Keller A
    Transfusion; 2012 Aug; 52(8):1806-13. PubMed ID: 22348664
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Innovations in blood donor screening and blood collection.
    Smith JW; Forsberg JE; Gilcher RO
    Curr Hematol Rep; 2002 Nov; 1(2):129-33. PubMed ID: 12901134
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blood component collection by apheresis.
    Burgstaler EA
    J Clin Apher; 2006 Jul; 21(2):142-51. PubMed ID: 15880369
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic apheresis in Sweden: update of epidemiology and adverse events.
    Norda R; Stegmayr BG;
    Transfus Apher Sci; 2003 Oct; 29(2):159-66. PubMed ID: 12941356
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantitative assessment of the anticoagulant in plasma units collected by plasmapheresis.
    Vurro F; Merolle L; Marraccini C; Parisi M; Canovi L; Erta B; Santachiara A; Bonvicini L; Giorgi Rossi P; Baricchi R; Pertinhez TA
    Transfusion; 2019 Jun; 59(6):2113-2120. PubMed ID: 30875439
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current topics on centrifugal plasmapheresis technologies.
    Omokawa S
    Ther Apher; 2001 Aug; 5(4):264-9. PubMed ID: 11724511
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of an automated plasmapheresis procedure for the harvest of equine plasma in accordance with current good manufacturing practice.
    Ziska SM; Schumacher J; Duran SH; Brock KV
    Am J Vet Res; 2012 Jun; 73(6):762-9. PubMed ID: 22620688
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Negative experiences and donor return: an examination of the role of asking for something different.
    Masser BM; Bove LL; White KM; Bagot KL
    Transfusion; 2016 Mar; 56(3):605-13. PubMed ID: 26472686
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The safety of plasma apheresis from donors recovering from COVID-19 infection in Japan.
    Kamo-Imai A; Togano T; Sato M; Kawakami Y; Inaba K; Shimazu H; Igarashi S; Tanaka K; Terada M; Kinoshita-Iwamoto N; Saito S; Kutsuna S; Hangaishi A; Morioka S; Takahashi K; Miyata S; Ohmagari N
    Transfus Apher Sci; 2023 Jun; 62(3):103687. PubMed ID: 36964059
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Donor reactions during DDAVP-stimulated plasmapheresis.
    Randels MJ; Strauss RG; Cordle D; Koerner TA; Floss AS
    J Clin Apher; 1992; 7(2):78-80. PubMed ID: 1429492
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Collection of hematopoietic progenitor cells from healthy donors].
    Bojanić I; Cepulić BG; Mazić S
    Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new apheresis procedure for the preparation of high-quality red cells and plasma.
    Knutson F; Rider J; Franck V; Joie M; Högman CF; Pamphilon D
    Transfusion; 1999 Jun; 39(6):565-71. PubMed ID: 10378835
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Donor safety in plasmapheresis.
    Lundsgaard-Hansen P
    Dev Biol Stand; 1980; 48():287-95. PubMed ID: 7274560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety of apheresis donation.
    Sniecinski IJ
    Infusionsther Klin Ernahr; 1987 Sep; 14 Suppl 4():52-6. PubMed ID: 3679530
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of plasmapheresis in France.
    Cazenave JP; Folléa G
    Hematol Cell Ther; 1996 May; 38 Suppl 1():S25-33. PubMed ID: 8933144
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improving the donation experience and reducing venipuncture pain by addressing fears among whole-blood and plasma donors.
    Gilchrist PT; Thijsen A; Masser BM; France CR; Davison TE
    Transfusion; 2021 Jul; 61(7):2107-2115. PubMed ID: 33904178
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Large volume donor plasmapheresis in inherited thrombophilia implicated in arterial thrombosis.
    Ovali E; Ratip S; Ozmenoglu M; Karti SS; Uçar F; Ukinç K; Yilmaz M; Koşucu P
    Transfus Apher Sci; 2003 Jun; 28(3):201-6. PubMed ID: 12725943
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.